ArticleAACE clinical case reports
METHOTREXATE TREATMENT FOR SARCOIDOSIS-INDUCED HYPERCALCEMIA.
Article in AACE clinical case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to corticosteroids and alternative therapies in sarcoidosis-related hypercalcemia: A guideline-lacking retrospective analysis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo present a patient with sarcoidosis-induced hypercalcemia who responded to methotrexate (MTX).
methodsThe described case includes clinical and biochemical reports.
resultsA 65-year-old woman presented with bilateral hilar lymphadenopathy and pulmonary nodules. Her calcium and phosphorous levels were 11.4 mg/dL and 3.5 mg/dL, respectively. Blood levels of 25-hydroxyvitamin D and parathyroid hormone were 68 nmol/L and 23 pg/dL, respectively. A diagnosis of sarcoidosis was confirmed by a lymph node biopsy that revealed non-caseating granulomas. Prednisone therapy was efficacious in normalizing the calcium level. However, hypercalcemia recurred when the prednisone dosage was tapered to below15 mg daily. Following initiation of MTX at 15 mg/week, prednisone levels were successfully titrated to 3 mg daily. After a temporary withdrawal of MTX therapy, calcium levels increased dramatically to 17 mg/dL.
conclusionMTX can be used as treatment for sarcoidosis-induced hypercalcemia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.